Search
Filter Results
- Resource Type
- Article29
- Book1
- Book Digital1
- Article Type
- Review1
- Case Reports5
- Biography3
- Historical Article3
- Result From
- PubMed29
- Lane Catalog1
-
Year
- Journal Title
- Acta Stomatol Belg16
- Protoplasma9
- Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M1
- Dtsch Arztebl1
Search Results
Sort by
- ArticleDiaz A, Baade PD, Valery PC, Whop LJ, Moore SP, Cunningham J, Garvey G, Brotherton JML, O'Connell DL, Canfell K, Sarfati D, Roder D, Buckley E, Condon JR.PLoS One. 2018;13(5):e0196764.BACKGROUND: Little is known about the impact of comorbidity on cervical cancer survival in Australian women, including whether Indigenous women's higher prevalence of comorbidity contributes to their lower survival compared to non-Indigenous women.
METHODS: Data for cervical cancers diagnosed in 2003-2012 were extracted from six Australian state-based cancer registries and linked to hospital inpatient records to identify comorbidity diagnoses. Five-year cause-specific and all-cause survival probabilities were estimated using the Kaplan-Meier method. Flexible parametric models were used to estimate excess cause-specific mortality by Charlson comorbidity index score (0,1,2+), for Indigenous women compared to non-Indigenous women.
RESULTS: Of 4,467 women, Indigenous women (4.4%) compared to non-Indigenous women had more comorbidity at diagnosis (score ≥1: 24.2% vs. 10.0%) and lower five-year cause-specific survival (60.2% vs. 76.6%). Comorbidity was associated with increased cervical cancer mortality for non-Indigenous women, but there was no evidence of such a relationship for Indigenous women. There was an 18% reduction in the Indigenous: non-Indigenous hazard ratio (excess mortality) when comorbidity was included in the model, yet this reduction was not statistically significant. The excess mortality for Indigenous women was only evident among those without comorbidity (Indigenous: non-Indigenous HR 2.5, 95%CI 1.9-3.4), indicating that factors other than those measured in this study are contributing to the differential. In a subgroup of New South Wales women, comorbidity was associated with advanced-stage cancer, which in turn was associated with elevated cervical cancer mortality.
CONCLUSIONS: Survival was lowest for women with comorbidity. However, there wasn't a clear comorbidity-survival gradient for Indigenous women. Further investigation of potential drivers of the cervical cancer survival differentials is warranted.
IMPACT: The results highlight the need for cancer care guidelines and multidisciplinary care that can meet the needs of complex patients. Also, primary and acute care services may need to pay more attention to Indigenous Australian women who may not obviously need it (i.e. those without comorbidity). - BookS. David Hudnall.Summary: "Gain a foundational understanding of complex hematology concepts with this thoroughly revised text. Hematology: A Pathophysiologic Approach, 2nd Edition, a volume in theMosby Physiology Series explains the fundamentals of this multi-faceted area in a clear and concise manner. It offers masterful explanations of hematopoiesis, immunology, hemostasis, hemoglobinopathy, metabolic disorders, genetics, and neoplasia from S. David Hudnall, MD, Professor Emeritus of Pathology and Laboratory Medicine at Yale University School of Medicine. Prof. Hudnall, who has practiced laboratory hematology and hematopathology for more than 30 years, has taught the principles of hematology to thousands of pre-medical undergraduates and medical students. Rich, clinically oriented coverage from cover to cover makes this text an ideal, problem-based way to learn about this complex subject"-- publisher's description.
Contents:
Brief overview of the hematolymphoid system
Hematopoiesis
Erythropoiesis and oxygen transport
Iron, heme, and hemoglobin
Hemoglobinopathy
Red blood cell metabolism and enzyme defects
Hemolytic anemia
Aplastic anemia and related disorders
Megaloblastic anemia
Myeloid cells
Immune system and related disorders
Genetic basis of hematologic neoplasia
Leukemia and related disorders
Lymphoma and related disorders
Blood coagulation
Platelets
Benign conditions of lymphoid organs
Blood transfusion and stem cell transplantation
Hematologic cancer therapy.Digital Access ClinicalKey [2024] - ArticleSassen MM, Remsen CC, Hess WM.Protoplasma. 1967;64(1):75-88.
- ArticleSchweiger HG, Dillard WL, Gibor A, Berger S.Protoplasma. 1967;64(1):1-12.
- ArticleBerger S.Protoplasma. 1967;64(1):13-25.
- ArticleUrl W.Protoplasma. 1967;64(1):26-48.
- ArticleBuckley IK, Porter KR.Protoplasma. 1967;64(4):349-80.
- ArticleRemsen CC, Hess WM, Sassen MM.Protoplasma. 1967;64(4):439-51.
- ArticleKoehler LD, Linskens HF.Protoplasma. 1967;64(2):209-12.
- ArticleArnott HJ, Walne PL.Protoplasma. 1967;64(3):330-44.
- ArticleRoss IK.Protoplasma. 1967;64(2):104-19.
- ArticleWohlfarth P.Dtsch Arztebl. 1967;64:603-7.
- ArticleVaifro Sabatelli G.Studi Fr. 1967;64:100-9.
- ArticleMayer R, Linker M, Fiévez C.Acta Stomatol Belg. 1967;64(2):193-204.
- ArticleDandoit R.Acta Stomatol Belg. 1967;64(4):469-559.
- ArticleMayer R, Libotte M, Ruppol P.Acta Stomatol Belg. 1967;64(1):33-52.
- ArticleSasserath F.Acta Stomatol Belg. 1967;64(2):289-301.
- ArticleQuataert G.Acta Stomatol Belg. 1967;64(1):55-69.
- ArticleLibotte M.Acta Stomatol Belg. 1967;64(1):71-98.
- ArticleVandervael A.Acta Stomatol Belg. 1967;64(1):13-6.